Pluri Inc.
PLURNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | $326,000 | $287,000 | $234,000 | — | $23,000 |
| Operating income | −$22.2M | −$22.2M | −$27.2M | −$41.6M | −$50.6M | −$29.5M |
| Net income | −$22.6M | −$20.9M | −$28.3M | −$41.2M | −$49.9M | −$29.2M |
| Total assets | $38.7M | $39.5M | $50.8M | $68.1M | $93.5M | $65.5M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$6.8M | $96,000 | $13.4M | $30.0M | $57.2M | $56.1M |
| EPS (diluted) | $-3.56 | $-3.99 | $-6.24 | $-1.28 | $-1.77 | — |
| Shares out. | 8.2M | 5.5M | 41.4M | 32.6M | 32.0M | 25.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1659.9%
- Net margin
- −1690.3%
- Return on equity
- 330.1%
- Return on assets
- −58.4%
- Return on capital (ROCE)
- −349.0%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.84
- Revenue growth (YoY)
- 309.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −11.3%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2007
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2005
- NT 10-Qmissed a reporting deadline ↗May 17, 2004
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2003
- NT 10-Kmissed a reporting deadline ↗Sep 29, 2003
- NT 10-Qmissed a reporting deadline ↗May 15, 2003
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Chutzpah Holdings LtdActivist (13D)May 1, 2026
- Shayna LpPassive (13G)Oct 14, 2025
- Franco-Yehuda ChenActivist (13D)Jun 9, 2025
- Yanay YakyActivist (13D)May 20, 2025
- Merchant Adventure Fund, L.P.Passive (13G)Apr 16, 2025
- Gunn John A.Passive (13G)Feb 14, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Manieu Alexandre WeinsteinDirector | Mar 31, 2026 | Grant | 312,500 | $2.00 |
| Manieu Alexandre WeinsteinDirector | Dec 8, 2025 | Grant | 625,000 | $2.00 |
| Manieu Alexandre WeinsteinDirector | Dec 4, 2025 | Grant | 519 | $0.00 |
| Ajchenbaum EitanDirector | Dec 4, 2025 | Grant | 668 | $0.00 |
| Yanay YakyOfficer — Chief Executive Officer | Dec 4, 2025 | Grant | 6,588 | $0.00 |
| Levi Rami AvrahamDirector | Dec 4, 2025 | Grant | 653 | $0.00 |
| Zalts LiatOfficer — Chief Financial Officer | Dec 4, 2025 | Grant | 3,660 | $0.00 |
| Shemesh-Rasmussen MaitalDirector | Dec 4, 2025 | Grant | 699 | $0.00 |
| Aberman ZamiDirector | Dec 4, 2025 | Grant | 346 | $0.00 |
| Manieu Alexandre WeinsteinDirector | Feb 25, 2025 | Grant | 10,250 | $0.00 |
| Ajchenbaum EitanDirector | Nov 12, 2025 | Grant | 11,685 | $0.00 |
| Yanay YakyOfficer — Chief Executive Officer | Oct 15, 2025 | Grant | 39,050 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 17,621 | 1.8 | -14.0% |
| Apr 30, 2026 | 20,487 | 3.1 | -15.1% |
| Apr 15, 2026 | 24,130 | 8.5 | -5.0% |
| Mar 31, 2026 | 25,407 | 3.6 | -2.9% |
| Mar 13, 2026 | 26,156 | 5.4 | -8.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Entered a material agreement · Unregistered equity saleMar 27, 2026
- Other material eventMar 2, 2026
- Delisting / listing-standard noticeJan 22, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Other material eventDec 9, 2025
- Director / officer changeOct 16, 2025
- Other material eventSep 12, 2025
- Director / officer changeSep 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTJun 1, 2026
- 10-QQUARTERLY REPORTMay 14, 2026
- 4May 4, 2026
- SCHEDULE 13D/AMay 1, 2026
- ARSFORM ARSApr 23, 2026
- DEFA14ADEFINITIVE ADDITIONAL MATERIALSApr 23, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 23, 2026
- 8-KCURRENT REPORTMar 27, 2026
- 8-KCURRENT REPORTMar 2, 2026
- 10-QQUARTERLY REPORTFeb 12, 2026
- 8-KCURRENT REPORTJan 22, 2026
- 4Jan 5, 2026
- SCHEDULE 13D/AJan 5, 2026
- SCHEDULE 13D/ADec 15, 2025
- 8-KCURRENT REPORTDec 9, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.